Search for other papers by Jiwen Yang in
Google Scholar
PubMed
Search for other papers by Yayin Huang in
Google Scholar
PubMed
Search for other papers by Bohan Dong in
Google Scholar
PubMed
Search for other papers by Yunhai Dai in
Google Scholar
PubMed
in vitro . Introduction Thyroid cancer is a common endocrine malignant cancer ( 1 ). The survival of patients with thyroid cancer has improved with the combined therapy of surgery and radioactive iodine (RAI) therapy. However, the
Search for other papers by Wei Sun in
Google Scholar
PubMed
Search for other papers by Boyuan Zheng in
Google Scholar
PubMed
Search for other papers by Zhihong Wang in
Google Scholar
PubMed
Search for other papers by Wenwu Dong in
Google Scholar
PubMed
Search for other papers by Yuan Qin in
Google Scholar
PubMed
Search for other papers by Hao Zhang in
Google Scholar
PubMed
studies have reported benefits of PCLND in patients with cN0. For example, PCLDN can help to accurately diagnose tumor-node-metastasis (TNM) staging, help decide on the use of thyroid-stimulating hormone (TSH) suppression therapy or radioactive iodine (RAI
Search for other papers by Changjiao Yan in
Google Scholar
PubMed
Search for other papers by Meiling Huang in
Google Scholar
PubMed
Search for other papers by Xin Li in
Google Scholar
PubMed
Search for other papers by Ting Wang in
Google Scholar
PubMed
Search for other papers by Rui Ling in
Google Scholar
PubMed
. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial . Lancet 2014 384 . ( https://doi.org/10.1016/S0140-6736(14)60421-9 ) 24768112
Search for other papers by Katerina Saltiki in
Google Scholar
PubMed
Search for other papers by Elli Anagnostou in
Google Scholar
PubMed
Search for other papers by George Simeakis in
Google Scholar
PubMed
Search for other papers by Sofia Kouki in
Google Scholar
PubMed
Search for other papers by Anastasia Angelopoulou in
Google Scholar
PubMed
Search for other papers by Leda Sarika in
Google Scholar
PubMed
Search for other papers by Alexandra Papathoma in
Google Scholar
PubMed
Search for other papers by Maria Alevizaki in
Google Scholar
PubMed
metastases from PTC were present in 2/9 patients (the tall cell variant and one classical PTC). Three out of 9 patients received Radioactive Iodine therapy. All patients are in remission concerning PTC. Of the non-exon 8 carriers, only 1/48 (2.1%) had
Search for other papers by Wei Li in
Google Scholar
PubMed
Search for other papers by Qing Huang in
Google Scholar
PubMed
Search for other papers by Danyang Sun in
Google Scholar
PubMed
Search for other papers by Guizhi Zhang in
Google Scholar
PubMed
Search for other papers by Jian Tan in
Google Scholar
PubMed
) ( 1 ). Through surgery and radioactive iodine ablation, most PTC patients have a good prognosis; however, a significant proportion of patients have persistent or recurrent disease and suffer from frequent recurrences or even distant metastases, leading
Search for other papers by Bilal B Mughal in
Google Scholar
PubMed
Search for other papers by Jean-Baptiste Fini in
Google Scholar
PubMed
Search for other papers by Barbara A Demeneix in
Google Scholar
PubMed
chlorine and bromine. Interestingly, THs are the only complex halogenated (iodine) molecules produced by and necessary for vertebrate homeostasis, making TH physiology highly vulnerable to EDCs. Halogen-substituted phenolic moieties can mimic natural THs